Matthew Orlando serves as General Counsel at KENVUE Inc., the world's largest pure-play consumer health company, where he leads a global legal team responsible for corporate governance, regulatory compliance, intellectual property, and risk management. With over 20 years of experience in the consumer products and healthcare sectors, Orlando joined KENVUE following its 2023 spin-off from Johnson & Johnson, bringing deep expertise from his prior roles at Johnson & Johnson, where he advised on multibillion-dollar transactions, mergers, and acquisitions. A graduate of Harvard Law School and holder of a bachelor's degree in economics from the University of Pennsylvania, he began his career at Cravath, Swaine & Moore LLP, specializing in complex litigation and antitrust matters. Throughout his tenure, Orlando has spearheaded transformative initiatives, including the legal structuring of KENVUE's landmark initial public offering, which raised over $3.8 billion and marked one of the largest consumer health IPOs in history. His achievements also include navigating high-stakes regulatory challenges across the FDA, FTC, and international bodies, resulting in successful product launches and defense of key trademarks for iconic brands like Tylenol, Neutrogena, and Listerine. Recognized as a leading lawyer by Chambers USA and The Legal 500, Orlando has been instrumental in fostering a culture of ethical compliance and innovation at KENVUE. In his current role, Orlando collaborates closely with the executive leadership team to drive sustainable growth, mitigate geopolitical risks, and support the company's ambition to deliver trusted health solutions worldwide. His strategic counsel has enabled KENVUE to expand into emerging markets while maintaining rigorous standards in supply chain transparency and ESG initiatives, positioning the company for long-term leadership in consumer health.